viagra tablets are the invention by Pfizer, Inc., whose popularity is not only down to their efficiency to produce rock-hard erection among a group of men suffering from a kind of impotence known as erectile dysfunction, but also because they have a seeming knack for reinventing themselves.
A report emanating from a hospital in Tyneside, Newcastle on the 15th of February 2007 told of how Viagra tablets were used to save the life of an infant.
According to the report, Lewis Goodfellow had weighed about 1pound and 8 ounce after been born prematurely at 24 weeks. The oxygen supply to Lewis’s bloodstream was not enough because his lungs had failed.
As a last ditch effort to save young Lewis’s life, the doctors at the Royal Victoria Infirmary, the hospital where Lewis had been born, had decided to administer Viagra, the citrate salt of Sildenafil Citrate, on the baby.
The fact that Viagra could open up tiny blood vessels in the baby’s lungs to allow for oxygen to be absorbed into the bloodstream, apparently, must have informed the doctors’ decision.
After saving young Lewis’s life with the novel effort, Alan Fenton, consultant neonatologist at the hospital, explained their decision thus:
‘The problem with most prematurely born babies that have difficulties with their breathing is that not enough blood is supplied to their lungs to allow for the circulation of oxygen to the other parts of their body, even in cases where oxygen is blown into their lungs to help them. What Viagra does is that it could help in opening up the blood vessels so that oxygen could be captured and be subsequently distributed to the rest of the body.’
Viagra tablets, in line with keeping to their headlines-grabbing tradition, were again in the news on the 14th of February, 2007 when a pilot scheme to trial the sale of the drug over-the-counter was carried out by Boots the chemist.
Under the scheme, three pharmaceutical stores in Manchester, England, would be stocked with Viagra tablets, and the scheme will afford those who want to buy viagra online with no prescription the opportunity to do so. If successful, the scheme would be carried out on a national scale and Viagra tablets would be made available to all the pharmaceutical stores nationwide.
Of course this does not mean that standard ethical practice would be discarded in dispensing the drug, as customers who want to buy Viagra tablets at these stores, but who do not have prescription, would be asked some salient questions relating to their suitability to buy the diamond-shaped blue pills.
Before a customer can buy a packet of four Viagra tablets, for example, he is expected to give out information on his medical history to the pharmacist, and also present himself for blood pressure, cholesterol and glucose levels, tests.
A positive angle to this novel scheme is that it avails the vast number of people who couldn’t get prescription for the blue pills, but who nevertheless want to buy Viagra tablets a great opportunity to be part of the Viagra revolution.
Out of the estimated 3 million men in Great Britain suffering from erectile dysfunction, according to Boots, only 10 percent of this group receive treatment. The scheme would make more Viagra tablets available to ease the problem of the vast population of the untreated class of people between the ages of 30 and 65 that would be eligible to buy.
Any man who desires a regular supply of Viagra tablets would be made to consult with a doctor at a fairly affordable price of about 35.5 pounds. And once he is certified fit to buy the drug, it would be made available to him at the cost of 21.25 tablets per 4-packets pack.
Filed under Blog, Sildenafil Citrate by
viagra as an effective Erectile Dysfunction (ED) treatment
Ed Treatments No Longer Limited! Try Out the Options Available
Erectile dysfunction became more popular amongst the common man not because of its nature but because of the treatments that were invented for the disease within the space of the last ten years. Erectile dysfunction was a matter of great concern and worry among the common man because earlier there were no convincing treatments for the disease. But now oral ED pills are doing very well as regards to ED cure.
Though the objective of all the oral ED drugs is the same, their components are slightly different. The first phenomenal ED drug to be invented, as we all know, was pfizer viagra. This ED drug inspite of being extremely popular and effective in ED treatment, proved to be of little use to a considerable number of ED patients. Not only ED, this happens in case of patients suffering from other diseases also. There are many people who cannot be administered the most popular drug of a particular disease, as the drug might not suit them. Similarly in case of ED also there are patients who cannot be treated with Viagra. These patients are often collectively termed as the Viagra non responders.
Therefore for these non responders there had to some kind of an equally effective alternative or for that matter alternatives. The medical giants started working on ED medications that could be as effective for those who cannot be treated by Viagra and also for those who can be. As a result today we have three prominent ED pills that are collectively thought to be the best form of ED cure.
These new ED cures are however not devoid of the side effects that their predecessor had. What they did was that they concentrated on developing some kind of an advantage or advantages over their predecessor. Something special and extraordinary that could not be found in Viagra.
The marketing strategy of these competitors bore fruits as today all of them are surviving in the market for ED cure. They have takers and their set of customers. All these drugs have even ventured into the online pharmacies with the hope of getting their product right into the bedroom of the customers, where they are actually meant to be! One thing that is however common with all the ED drugs is their abuse. Almost all the ED drugs are used for purposes that they are not meant to serve.
Well, coming back to the topic of the Viagra competitors, the latest one to join the band wagon was Bayer Levitra. Counted among one of the cheapest ED drugs, Levitra online also has the advantage of being applicable to the patients of hypertension and diabetes. People can order levitra once they are approved the Levitra prescription. Please do not go for online pharmacies which claim to sell cheap levitra, always buy levitra from a well known online store selling the FDA approved levitra pills.
Encore Revive Premium – As seen on TV – Proven Impotence Treatment Covered by Medicare
Filed under Impotence, Prescription Viagra, Sildenafil Citrate by
Can viagra cause death?
A Life Guard
The way Viagra works, is to improve the flow of blood that runs around the body by incrementing the level of a protein known as phosphodiesterase 5 that is located in the phallus and squeezes the arteries in that area. But, this protein is also found in two other areas of the human body, the lungs and the right ventricle of the heart. Pulmonary hypertension influences the blodd stream to the lungs, therefore restricting the arteries and stretching the right ventricle of the heart. It is similar in diagnosis to blood hypertension, but the extra exercise the heart must do to pump the protein around the body in the blood often causes tiredness, dyspnea and in extreme cases can bring about death of the patient. Having blood hypertension is easily manageable, and with the correct drug patients can increment their life by approximately twenty years. Nevertheless, if a patient suffers from pulmonary hypertension, their life is significantly decreased. In the extreme cases, a patient might only have 3 years without the right medication, and this has a damaging effect on their life quality. No essential testing was executed with this medical condition, as it was difficult to determine. Then, in 2002 experiment was executed on a number of patients who sufered from this illness. ForegoingPrior tests with other medication focused on healthy hearts, and did not get successful results because it was hard to strengthen the right ventricle combining with decreasing blood pressure and unnerving the lungs. This study included giving patients controlled dosage of Viagra, and produced unexpected results. Viagra was identified to be extremely successful in improving the heart function of patients who have a affected right ventricle, and reduced the hypertension in their lungs. Because Viagra is a completely sure and natural treatment that works with the chemical imbalances in the blood run, doctors at Glasgow’s Yorkhill Children’s Hospital prescribed this medication to children who were suffering from extreme pulmonary hypertension. The result was astonishing. Many of these babies would not have made it without this interference of Viagra, and the treatment has provided a breakthrough with improving patient drug. Viagra is also useful in cases such as lung transplant surgery, where the right ventricle can often fail if the lung is rejected. Viagra is thought to be one of the most famous and successful treatment in states such as erectile dysfunction, and now it has been proved to be successful in therapy for pulmonary hypertension. Widening the blood vessels and alleviating the breathing difficulties of the patient is a modern outbreak. Because Viagra has no notable side effects, it can now be given to many patients of all age categories who experience various blood related medical conditions.
brokencyde – Blame it on tom
Filed under Blog, Buy Viagra, Impotence by
Does viagra improve the heart condition?
“me-too†Drugs: Good or Bad?
Introduction
A drug that is structurally very similar to already known drugs, with only minor differences. The term "me-too" carries a negative connotation. However, me-too products may create competition and drive prices down1.
The majority of the new products the industry puts out, are “me-too” drugs, which are almost identical to current treatments but “no better than drugs already on the market to treat the same condition.” Around 75 percent of new drugs approved by the FDA are me-too drugs. They can be less effective than current drugs, but as long as they’re more effective than a placebo, they can get the regulatory green light2.
This isn’t surprising at all, as someone who works in the field, but these so-called “me-too” drugs, which are reportedly better than their forebears, is driving costs. A “me-too” drug is a drug that has its origins in another drug. Probably the most famous example of this is Prilosec (“The Purple Pill”) and Nexium (“Today’s Purple Pill”). Prilosec’s active ingredient is omeprazole. Nexium’s active ingredient is called esomeprazole. The difference is that Nexium is the left-handed version of omeprazole. In chemistry, S stands for sinister, which means the molecular conformation has a left-handed orientation. (D would be right handed.) So this S-omeprazole is one half of the mixture that comprises its predecessor. By specifically picking only the S conformation, the drug is made more potent. This sounds great, but its efficacy is only marginally better than Prilosec-, which has a generic version, and costs about a third less than Nexium. Some other “me-too” drugs are: Claritin (loratidine) and Clarinex (desloratidine), Celexa (citalopram) and Lexapro (escitalopram)3.
What are "Me-Too" drugs?
Ever since the advent of modern chemotherapy, when drugs were discovered and developed through the process of screening thousands of molecules for a variety of disease conditions, using animal models, there has been a growing criticism that too many molecules were developed with similar chemical structure and the same pharmacological profile, with very little to distinguish them from each other in terms of their therapeutic utility. In other words, once the first breakthrough discovery is made of a new pharmacological activity for a new molecule, subsequent years saw the emergence of a host of new molecules or "me-too" drugs from the same chemical class and possessing the same pharmacological profile.
Such follow-up drugs have been termed molecular modifications, molecular roulettes or copycats, the development of which are alleged to be motivated by purely commercial considerations. They are also deemed to involve lower levels of innovation, compared to the original molecule. It is important to analyze in a historical perspective the end results of such efforts in different therapeutic areas of developing new molecular entities, as later generation products, after an initial breakthrough discovery has been made and the technical, medical and commercial merits of developing such drugs.
Development of "Me-Too" drugs
The success rate in the discovery of new chemical entities with fundamentally new chemical and biological profiles of activity are very low. In fact, even chemical entities within the same structural class of an approved drug are becoming rare now, compared to the period of sixties to eighties. In 2001, $ 26 billion was spent on developing new drugs and the U.S. FDA approved only 9 new chemical entities. At the same time, two thirds of the drugs approved from 1989 to 2000 were modified versions of existing drugs or even identical to those, in newer forms and formulations4.
Of the 1,035 drugs approved by FDA during 1989 to 2000, only 361 or 35% contained new active ingredients. Of these, only fewer than half were granted priority review status by the FDA. One impression is that these drugs are slightly altered versions of existing drugs, with little to offer in terms of better activity or tolerance, let alone new pharmacological profiles. The implication is that such drugs are developed, as patents on top-selling original drugs run out and not many truly new medicines are discovered. The indication that many of these drugs do not offer any major advantages over existing drugs is given by FDA's unwillingness to grant priority review for most of them.
On the other hand, conventionally, the Regulatory Agencies, including the FDA, are not obliged to consider better efficacy over existing drugs as a criterion for approval; rather, they require only the establishment of efficacy and safety of the new drug over a placebo.
How good are they?
Notwithstanding such perceptions, historically, many "me-too" drugs have proved to be considerably better than their original counterparts. Examples are a series of generations of beta-blockers, which came up after the original drug Propanalol was discovered by ICI, with most of them having merits in terms of better efficacy, cardio-selectivity and safety. Ranitidine, the first follow-up drug after the introduction of the first H-2 receptor antagonist, Cimetidine, was followed by Famotidine and in each case these "me-too" drugs had notable merits over the original drug.
Apart from the major breakthrough in the development of orally active beta lactam antibiotics of the Penicillin and Cephalosporin class, within the same oral derivatives, there have been considerable improvements brought about by change in the side chains incorporated by condensation of specific agents with 6-APA, 7-ADCA and 7-ACA. A whole new range of broad-spectrum antibiotics of these structural classes could thus be developed. In each of the major classes of antibiotics, classified according to the mechanisms of their action, namely inhibition of cell wall synthesis (Beta Lactams, Vancomycin), inhibition of bacterial protein synthesis (Erythromycin, Tetracycline, Streptomycin), inhibitors of DNA or RNA replication (Quinolones, Rifamycins), inhibition of Folate Coenzyme biosynthesis (Sulfa drugs, Trimethoprim), there have been several "me-too" drugs marketed.
An important recent example to show that 'me-too" drugs need to be developed is the case of the oral hypoglycemic drug Troglitazone, approved as an anti-diabetic drug in 1997. The drug was withdrawn from the market following reports of unacceptable hepato-toxicity. The follow-up "me-too" drugs, Rosiglitazone and Pioglitazone are much less toxic and are today widely used. If these drugs were not developed, the withdrawal of Troglitazone would have left a major therapeutic gap in anti-diabetic therapy.
"Me-Too" drugs: Strategies for New Drug Research for Indian Companies
Breakthrough innovations in pharmaceutical industry, of new drugs, such as the first beta blocker, the first NSAID, the first of each class of Antibiotics, Calcium Channel blockers, ACE inhibitors, Sulfonyl Ureas, Biguanides, Insulin, Glitazones, Glinides, Tricyclic Anti Depressants,major and minor Traquillisers, Selective Serotonin Receptor inhibitors, H-1 and H-2 Receptor antagonists, Proton Pump inhibitors etc are relatively rare and even though a few of the original drugs under these classes are still very much in use, they have been superceded in most cases, by later generation products, many of them "me-too". The newer drugs are discovered both through incremental innovations on the original drugs as well as through new research.
Generally the original discovery leads to feverish activity both within the innovator company as well as in Competitors' laboratories, to develop better products in the same therapeutic category. The essential caveat for commercial success, however, is that the newly discovered molecules should meet the minimum standards of patentability. For example within three years of the discovery of the highly successful Sildinafil Citrate (Viagra), three more new versions for the same indications have been patented and developed5.
Me-too drugs also provide therapeutic advantage6. For the practicing physicians, there's the benefit of established drug MoA with a "me-too" medication, coupled with clinical studies that – hopefully – show patient-centered benefits such as better adverse events profiles, less frequent dosing, less bothersome potential for drug/drug interactions, and so forth. A "me-too" drug is a helluva lot easier to incorporate in practice than a totally novel medication7.
"Me-Too" drugs: The hidden dynamics
The most common criticism of drug development centers on the so-called "me-too" drugs that employ the same biological mechanism as pioneer brands. This involves a lot more than such high-profile targets as the anti-ulcer drug Nexium. We should be thinking about antidepressants, cholesterol-reducing drugs, diabetes treatments, anti-psychotics, and other therapeutic categories that have seen both blockbuster sales and rapid innovation. There is quite a bit of evidence that follow-on drugs do a lot of patients a lot of good. The newer statins, for example, often out-perform the older ones in clinical trials where the endpoints are the number of heart attacks and deaths prevented.
Me-too drugs are also a powerful tool for cutting health care costs. We should be glad that our research industry does not target only brand new biological mechanisms. That would be a very expensive business model indeed. Fortunately, the industry also works on marginal improvements, exploiting opportunities to make drug therapy better and sometimes opening the door to really radical improvements that happen to lie more or less next-door, scientifically speaking. In the meantime, we get price competition as a by-product. Me-too's almost always undercut the prices of the pioneer drugs.
Another part of the me-too story gets almost completely ignored even though it is extraordinary important. For me-too manufacturers, advancing the science is a way to gain a competitive advantage. The classic example is the statin class of cholesterol drugs. Research on one of the follow-on drugs (Pravachol) demonstrated for the first time that using a statin to reduce cholesterol would actually prevent deaths from heart attacks, something that had previously been assumed without proof. Additional trials for several statins, including Lipitor, the formidable challenger to Zocor and Pravachol, have demonstrated that serum cholesterol is far more important than almost anyone thought (for preventing strokes, for example).
There are lots of other stories about the benefits of new research from me-too drugs, but they are part of a larger story: new uses for old drugs. The data showing a slowdown in new drug approvals exclude essential information: discoveries of new uses for old drugs. This kind of discovery has become so common that it amounts to a "new-use" revolution. One of the scientific ironies of the new era of pharmaceutical research is that as drugs become more tightly targeted on biological mechanisms, their uses actually become more diverse. This is because the body typically uses specific mechanisms over and over again, sometimes in what appear to be completely unrelated ways.
Consider the SSRI antidepressants. A recent Science article on the diverse and unexpected applications of drugs that fiddle with serotonin reuptake which is what the SSRIs do concluded that the very term "antidepressant" is misleading because there is no scientific reason to think of this drug as being just for depression. Fighting depression just happened to be the first really useful condition that was explored for this very interesting class of drugs.
Another example is the Cox-2 inhibitors like Celebrex (and Vioxx, which is important in this story and may return to the market partly for this reason). These were invented to relieve arthritis pain. But the Cox-2 enzyme turns out to be important for lots of things including cancer and Alzheimer's. Clinical trials to exploit these leads have been underway for years. Celebrex has already been approved for reducing the risk of colorectal cancer, and Vioxx has also achieved promising results. Of course, the big news recently has been that these drugs may cause heart attacks. But even here, me-too economics is of surpassing importance. The traditional NSAIDS (non-steroidal anti-inflammatory drugs) like Alleve and Advil may have the same heart attack risks. The potential risk has been there for decades, but only the new drugs-the Cox-2s-have been put through large-scale long-term clinical trials because those are the only ones still under patent. This is an example of how me-too drug development adds importantly to the research base. Thanks to the me-too's, we are learning about NSAIDs, heart attacks, cancer and probably much more.
Also dominated by new uses are the new-targeted cancer drugs, which attack such specific biological mechanisms that they avoid killing every fast-growing cell in sight (as traditional chemotherapy tends to do).
The implications are clear. The annual count of new drug approvals will only show a tick when a new cancer drug or a new statin gets its very first approval. But a new use for an old drug can be as valuable as an entirely new drug, or even more valuable when you consider that we know more about the safety profile of old drugs and one drug will sometimes do the work of two (preventing both heart attacks and strokes, for example)8.
Me-too products can sometimes have important advantages on tolerability or dosing. It could help create more competition and lower the price. If you have five me-toos, possibly the sixth is something that is a little better. That is for the plans to decide on behalf of their patients. And even if it has the same mechanism of action, more competition could help drive down the price of the entire class. That’s an important influence, with potentially an improvement in health from greater access.
How bad are they?
Even though the major problem of antibiotic therapy, namely drug resistance cannot be addressed by the development of "me-too" drugs, due to the propensity of the same class to develop cross resistance; in most cases, the new semi-synthetic derivatives had distinct advantages over the earlier ones. Thus, for example, the first generation Cephalosporins are useful for gram-positive infections, while the second-generation drugs cover a broader spectrum including gram-negative organisms. The third generation drugs provide resistance against the beta lactamase enzyme, as well as acting against some of the most intractable infections, such as those caused by Pseudomonas and Klebsiella strains.
Even while the pharmaceutical industry turns out families of me-too drugs for relatively mild conditions in affluent people, it pays almost no attention to serious diseases, such as malaria, affecting impoverished people. It also gives short shrift to less profitable drugs, so there now are shortages of some vaccines and life-saving drugs9.
The big problem with me-too drugs is that they are chemically very similar to other drugs already available, yet they are marketed as if they were important new breakthroughs, with very high prices. Many new, expensive me-too drugs are not necessarily better than older and less expensive drugs. Most of the time they are compared with placebos and not older drug comparisons.
"Me-too" drugs are responsible for 80% of increased spending in recent years, and on average they are four times more expensive than the comparable, older alternatives10. By Patented Medicines Pricing Review Board's (PMPRB) definitions, at the time of their introduction “me-too” drugs were judged to provide moderate, little or no improvement – in terms of effectiveness and safety – compared to older alternatives. However, on average, “me-too” drugs cost about 2.5 times as much per prescription as comparable older drugs. The question is whether the perceived or real differences justify the increased costs. New drugs do have a role in some situations and for some patients. However, it makes sense to use the older equally effective drugs whenever possible11.
Changing FDA rules to discourage me-too drug approvals would make R&D far more expensive, would discourage competition and therefore raise healthcare costs, and would forestall the wave of new research that has revolutionized our scientific understanding of the therapeutic categories where competition has been most intense.
Conclusion
New drugs are not required to improve on old ones, and there’s usually no way to know whether they do. Although the FDA must test drugs before they are marketed, they don’t need to be compared with similar drugs already on the market. The FDA only requires they be reasonably safe and better than nothing-a low standard indeed. This loophole in FDA regulations opens the door for an unlimited number of me-too drugs, which are easier to develop than innovative drugs.
Given everything, it should come as no surprise that these more expensive “me-too” drugs cost the medical industry money. The prevalence of the me-too's really says an awful lot about the lack of innovation within the pharmaceutical industry. If you look at the new drugs marketed over the last six years, 78 percent weren't even new chemical compounds. They were just new combinations or different formulations of old drugs. And 68 percent were classified by the F.D.A. as unlikely to be improvements over drugs already on pharmacy shelves.
At the same time, there are shortages of some important drugs that the pharmaceutical companies aren't much interested in making because they are not as profitable as the me-too's. But the companies don't have to turn out needed drugs, if they are not lucrative. And they don't.
References
1. http://www.medterms.com/script/main/art.asp?articlekey=33748
2. http://www.motherjones.com/news/qa/2004/09/09_401.html
3. http://polyscience.org/2005/09/me-too-drugs
4. http://www.shvoong.com/books/465475-me-too-drugs
5. http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=14604§ionid=46
6. http://direct.bl.uk/bld/PlaceOrder.do?UIN=162532605&ETOC=RN&from=searchengine
7. http://www.archivum.info/sci.med/2005-09/msg00257.html
8. http://www.aei.org/publications/filter.all,pubID.27443/pub_detail.asp
9. http://blogs.wsj.com/health/2007/05/17/in-praise-of-me-too-drugs
10. http://www.chepa.org/KnowledgeExchange/LabelleLectureship/tabid/84/Default.aspx
11. http://www.ti.ubc.ca/pages/letter59.html
Viagra amplifies the effects of a heart-protective protein
Filed under High Blood Pressure, Impotence, Sildenafil Citrate by
viagra is the popular erectile dysfunction treatment manufactured by Pfizer. An enormously successful drug which has been effective in making millions of men achieve rock-hard erection, cheap Viagra tablets were accidentally discovered by a group of pharmaceutical chemists working in Pfizer’s research facility in Sandwich, Kent.
Such is the potency of the blue pills that it is generally believed that men who use real Viagra tablets to correct their erectile problems, are also indirectly remedying the emotional issues that could be engendered by the ED.
Viagra tablets online prolong erection for up to four hours by slowing down the rate at which the blood that enters the cigar-shaped, tubular structures in the penis – known as the corpus cavernosa – through the constriction of the veins. This allows for the trapping of the blood in the penis.
In recent times, there is a growing myth associated with the drug as an effective treatment for a host of other sexual dysfunctions, especially in the area of prolonging ejaculation, and this has resulted in more and more people looking to buy Viagra cheap online in the hope of solving their sexual problems.
However, people who buy viagra online with no prescription have been advised against doing so, as it not only contravenes Pfizer’s edict for the drug to be sold on prescription, but it poses a great menace to the health of the user.
Rather than the advice quelling this notion, though, a new wave of belief could be driving the sale of Viagra tablets in the UK. According to a host of websites that hold discussion platforms on sexual dysfunction issues, feelings about the ability of the drug to increase the size of the penis have been streaming into the sites from readers.
A respondent, in answering to the issue, cautioned that buying viagra online next day delivery as a penis enlargement drug was not the way to go, though the diamond-shaped blue tablets could be potent in producing erection.
However, the respondent added that what most of the readers experienced might have been the actual sizes of their fully erect penises, and that the penises had been stretched beyond the partially erect state they normally experienced without the aid of Viagra tablets online. The dozens of reports still being sent about how readers feel that their penises became bigger after using Viagra, indicate that this feeling is not about to diminish anytime soon.
"My wife said that my penis felt bigger than it has ever been, after I used viagra pills."
"My girlfriend has noticed a marked improvement on both the thickness and length of my penis."
"My penis is bigger and harder than ever before and my shoots are farther than it has ever been because of Viagra."
"I’m bigger and longer in size and I last much longer than I used to, since I started using Viagra."
Could all these be true? One would ask.
These reports, if they are to be believed, could be responded to by still corroborating the earlier impression thus: Anyone experiencing for the first time such a full erection as produced by herbal viagra tablets, could have a feeling of apparent increase in the size of his penis, a feeling that his normally partially erect penis wouldn’t have given. In addition, being so hard could actually feel like the penis has grown bigger to the partner.
To put this discussion to bed, suffice it to say that no clinical studies exist to buttress the feeling that Viagra enlarges the penis. If the consistency of these reports is anything to go by, however, the issue should be researched on.
Filed under Penis Enlargement by
viagra and Erectile Dysfunction (ED)
.jpg)
How to Beat Erectile Dysfunction
Erectile Dysfunction (ED) also known as impotence is a condition that affects men. This is when a man cannot get an erection or if he does he can not hold it for long. Many men have suffered from this dysfunction at one point or another, but the good news is that, though it cannot be treated overnight, it can still be treated and a man can enjoy having sex with his partner. Many men have viewed this as something that is very embarrassing and are not ready to discuss this with their partners. They pretend not to be interested in sex so that their partners does not find out they have a sexual problem. The first step however towards feeling better and getting better is talking about it with your partner and a doctor. This way, you will be on your way to recovering.
You can also deal with erectile dysfunction by getting drugs for it. Drugs like Viagra, Levitra and Cialis can be used to treat this condition in men. All this drugs have been tested on men and the clinical result of Cialis has shown that it is more effective than Viagra and Levitra. This however does not mean that Cialis is the drug that you should go for if you have erectile dysfunction. You will still need to test all the three drugs that are available to see which one best works for you. Do not forget to include the help of your doctor when making a decision of what best works for you.
If you do not want to get an erectile dysfunction, you should try to keep your life as stress free as possible. This is because researcher have found out that stress contributes to 50 percent of the erectile dysfunction cases. Most men who had this dysfunction when asked whether they were worried about something always gave out something that worried them. It ranged from money matters to family issues. Stress affects our health in all kinds of way. If you feel something is stressing you out, talk to someone, try to solve it with someone else. Do not deal with problems alone. You might end up hurting your sexual life.
If you like smoking and drinking, you should keep it to a minimum level. Research has also shown that heavy smoking can cause an erectile dysfunction in men. This is because everytime you over drink and smoke you lower the production of the testosterone which is a steroid hormone that has a major sexual function in both men and women. The testosterone sort of give the men increased libido and energy and if you do not stay away from excessive drinking and smoking you might not be able to beat erectile dysfunction because you will lower the production of this hormone. Stay away from drinking, smoking and stress and be on your way to beating erectile dysfunction. Do not be afraid of using some of these drugs, they might even enhance your performance.
Natural and Free Erectile Dysfunction (ED) Treatments
Filed under Buy Viagra, Impotence by